Irritable Bowel Syndrome (IBS) Treatment Market - Top Companies and Manufacturers

Companies Dominating the Irritable Bowel Syndrome Treatment Landscape

Key players in the irritable bowel syndrome treatment market are adopting several organic and inorganic tactics to earn high profits. Leading companies are investing heavily in R&D for the production of advanced and reliable irritable bowel syndrome drugs to maximize their revenue shares. They are also collaborating with other players and research organizations to attract a wider consumer base through innovations. Industry giants are also employing regional expansion strategies to increase their market reach.

Some of the key players include:

Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Ardelyx, Inc.
Abbott Laboratories
Bausch Health Companies Inc.
Bayer AG
Ironwood Pharmaceuticals, Inc.
Johnson & Johnson
Sanofi S.A.
Sebela Pharmaceuticals Inc.
Novartis AG
Validus Pharmaceuticals LLC
AstraZeneca Plc
GlaxoSmithKline, Plc

Browse Key Market Insights with Data Illustration:

Irritable Bowel Syndrome Treatment Market Size, Growth Trends 2037

In the News

In June 2023, Ironwood Pharmaceuticals, Inc. announced that it received FDA approval for the use of LINZESS. LINZESS is effective for the treatment of functional constipation in patients aged between 6 to 17 years.
In October 2023, Sanofi S.A. and Teva Pharmaceuticals signed a collaborative agreement to co-develop and co-commercialize asset TEV’574 for the treatment of two types of inflammatory bowel disease, Ulcerative Colitis and Crohn's Disease.
In April 2022, Ardelyx, Inc. revealed the launch of IBSRELA an NHE2 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is one of the novel mechanism therapies to treat IBS-C in a decade.

Frequently Asked Questions (FAQ)

The global irritable bowel syndrome (IBS) treatment market will be valued at USD 3.9 billion in 2025.

Expanding at a CAGR of 8.8%, the global market is expected to increase from USD 3.6 billion in 2024 to USD 10.7 billion by 2037.

Some leading companies are Ardelyx, Inc., Abbott Laboratories, Bausch Health Companies Inc., Bayer AG, Ironwood Pharmaceuticals, Inc., and Johnson & Johnson.

The tablet segment is estimated to capture a strong 68.2% of the market share through 2037.

North America is expected to hold 36.4% of the global market share through 2037.

Irritable Bowel Syndrome (IBS) Treatment Market - Top Companies and Manufacturers

Companies Dominating the Irritable Bowel Syndrome Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the irritable bowel syndrome (IBS) treatment market?

What is the outlook for the irritable bowel syndrome (IBS) treatment market?

Who are the major key players dominating the irritable bowel syndrome (IBS) treatment market?

Which dosage form segment is expected to lead the irritable bowel syndrome (IBS) treatment market by 2037?

Which region will provide more business opportunities for the growth of the irritable bowel syndrome (IBS) treatment market in the future?